American College of Cardiology acknowledges potential concern over blood pressure medications and increased risk for coronavirus....
Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with coronavirus disease 2019 (COVID-19). Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients also may have severe cardiovascular damage. Angiotensin converting enzyme 2 (ACE2) receptors have been shown to be the entry point into human cells for SARS-CoV-2, the virus that causes COVID-19.
In a few experimental studies with animal models, both angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been shown to upregulate ACE2 expression in the heart. Though these have not been shown in human studies, or in the setting of COVID-19, such potential upregulation of ACE2 by ACE inhibitors or ARBs has resulted in a speculation of potential increased risk for COVID-19 infection in patients with background treatment of these medications.
This might partially explain why the death rate for people with pre-existing cardiovascular diseases is higher compared to people with respiratory disorders.
Related references for an against use of these drugs: https://www1.racgp.org.au/newsgp/clinical/ace-inhibitors-arbs-and-covid-19-what-gps-need-to
Considering most cases of hypertension is reversible using lifestyle approaches, isn't now the time to take personal responsibility rather than relying on the uncertainty of pharmaceuticals?
Consider taking this short risk assessment for the disease - COVID-19, which includes information on drugs that lower your ability to fight the coronavirus.
Thomas J. Lewis, Ph.D.